Boral Capital initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a Buy recommendation. Analyst Price Forecast Suggests 441.19% Upside As of November 21, 2024, the average one-year price target for Context Therapeutics is $7.52/share. The forecasts range from a low of $4.5...
2025-04-27 dailyforecast.net.,3317,2025-04-27 weibo.com.,3318,2025-04-27 articulate.com.,3319,2025-04-27 bitstamp.net.,3320,2025-04-27 d8ghbpr3r4dzt.cloudfront.net.,3321,2025-04-27 a-ads.com.,3322,2025-04-27 sonos.com.,3323,2025-04-27 outfit7.com.,3324,2025-04-27 kwaizt....